Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trialGary Middleton, John P. Neoptolemos, Fareeda Y. Coxon et al.|The Lancet Oncology|2014Cited by 374
A phase III randomized trial of chemoimmunotherapy comprising gemcitabine and capecitabine with or without telomerase vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer.Gary Middleton, John P. Neoptolemos, Juan W. Valle et al.|Journal of Clinical Oncology|2013Cited by 19
A phase III randomized trial of chemoimmunotherapy comprising gemcitabine and capecitabine with or without telomerase vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer.Gary Middleton, John P. Neoptolemos, Juan W. Valle et al.|Journal of Clinical Oncology|2013Cited by 18